In the United States, adaptogenic face creams are regulated as cosmetics under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as amended by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). This regulatory classification means no pre-market approval is required, but it also means your label and marketing claims must stay on the cosmetic side of the drug-intent line — a line the FDA takes seriously and that is easier to cross accidentally than most founders expect.
The drug-intent line: A cosmetic claim describes a product's effect on the appearance of the body. A drug claim describes an effect on the structure or function of the body. Examples of cosmetic-safe claims for an adaptogens face cream: 'gives skin a more rested appearance,' 'visibly reduces the look of fatigue,' 'helps skin look calm and refreshed.' Examples of drug-territory claims to avoid: 'reduces cortisol in the skin,' 'repairs the stress response,' 'treats inflammation.' The word 'treat' and any reference to a physiological mechanism (cortisol, HPA axis, inflammation pathway) are the most common triggers.
Required label elements under the FD&C Act and Fair Packaging and Labeling Act: (1) Product identity statement (e.g., 'Face Cream'). (2) Net quantity of contents in both US and metric units. (3) Name and address of the manufacturer, packer, or distributor. (4) Material facts — any warning required for safety (e.g., 'keep out of reach of children,' 'for external use only'). (5) INCI ingredient list in descending order of predominance, with water listed first and fragrance listed as 'Parfum' or individual components if allergen disclosure is desired.
MoCRA-specific requirements effective 2024: facility registration with the FDA (the manufacturer typically handles this), product listing submission (brand owner's responsibility in most structures), and a safety substantiation file maintained by the responsible party. For adaptogen extracts, the safety substantiation should include the extract's toxicological profile, its concentration in the finished formula, and any available dermal sensitization data.
California Prop 65 is a separate state-level obligation. Certain botanical extracts — including some mushroom species and root extracts that can carry trace heavy metals — may trigger Prop 65 thresholds for lead or cadmium. A finished-goods heavy metals test (ICP-MS panel) from an accredited lab is the standard way to clear this risk before launch.
EU labeling, if you plan to export: the EU Cosmetics Regulation (EC) No 1223/2009 requires a 12-digit CPNP notification for each product before sale, a Responsible Person (RP) established in the EU, an EU-format Product Information File (PIF), and a Safety Assessment signed by a qualified assessor. Some adaptogens are not on the EU positive or negative lists but exist in a gray zone; a regulatory consultant familiar with Annex II and III of the EU Cosmetics Regulation should review your specific ingredient list before you export.
Working with a manufacturer who has in-house regulatory affairs staff — something you can confirm when posting your brief on the AJ Cosmo Labs platform — is the most cost-effective way for an indie brand to navigate these requirements without hiring a full-time compliance consultant.
Read the full guide on Private Label Adaptogens Face Cream Manufacturer Low MOQ →